Baxter International Inc (BAX) Stake Decreased by B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund

B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund lowered its holdings in Baxter International Inc (NYSE:BAX) by 55.7% in the 2nd quarter, Holdings Channel reports. The firm owned 7,950 shares of the medical instruments supplier’s stock after selling 9,992 shares during the period. B.S. Pension Fund Trustee Ltd acting for the British Steel Pension Fund’s holdings in Baxter International were worth $587,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. BKD Wealth Advisors LLC increased its position in Baxter International by 1.8% during the second quarter. BKD Wealth Advisors LLC now owns 41,331 shares of the medical instruments supplier’s stock valued at $3,052,000 after acquiring an additional 732 shares during the last quarter. FineMark National Bank & Trust increased its position in Baxter International by 6.0% during the second quarter. FineMark National Bank & Trust now owns 13,239 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 753 shares during the last quarter. Drexel Morgan & Co. increased its position in Baxter International by 18.4% during the first quarter. Drexel Morgan & Co. now owns 4,887 shares of the medical instruments supplier’s stock valued at $318,000 after acquiring an additional 760 shares during the last quarter. Cpwm LLC increased its position in Baxter International by 22.8% during the second quarter. Cpwm LLC now owns 4,230 shares of the medical instruments supplier’s stock valued at $312,000 after acquiring an additional 784 shares during the last quarter. Finally, Knowledge Leaders Capital LLC increased its position in Baxter International by 1.0% during the second quarter. Knowledge Leaders Capital LLC now owns 79,384 shares of the medical instruments supplier’s stock valued at $5,862,000 after acquiring an additional 786 shares during the last quarter. Hedge funds and other institutional investors own 83.08% of the company’s stock.

A number of analysts have commented on the company. Argus restated a “hold” rating on shares of Baxter International in a research report on Tuesday, September 4th. Citigroup upped their price target on Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Piper Jaffray Companies upped their price target on Baxter International from $77.00 to $83.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. JPMorgan Chase & Co. upped their price target on Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $76.00 price target on shares of Baxter International in a research report on Friday, July 27th. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Baxter International presently has a consensus rating of “Buy” and a consensus price target of $76.00.

Shares of BAX opened at $77.69 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.62 and a quick ratio of 2.00. The stock has a market capitalization of $40.65 billion, a price-to-earnings ratio of 31.33, a P/E/G ratio of 2.06 and a beta of 0.74. Baxter International Inc has a 52 week low of $60.78 and a 52 week high of $77.85.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.06. The firm had revenue of $2.84 billion during the quarter, compared to analyst estimates of $2.83 billion. Baxter International had a return on equity of 16.63% and a net margin of 8.29%. The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 earnings per share. research analysts anticipate that Baxter International Inc will post 2.98 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Friday, August 31st will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Thursday, August 30th. Baxter International’s dividend payout ratio (DPR) is 30.65%.

In other news, SVP Scott Pleau sold 10,686 shares of the company’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $75.00, for a total value of $801,450.00. Following the completion of the transaction, the senior vice president now owns 26,349 shares of the company’s stock, valued at $1,976,175. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Carole J. Shapazian sold 5,400 shares of the company’s stock in a transaction dated Wednesday, August 8th. The stock was sold at an average price of $72.97, for a total value of $394,038.00. Following the completion of the transaction, the director now directly owns 15,248 shares of the company’s stock, valued at approximately $1,112,646.56. The disclosure for this sale can be found here. In the last ninety days, insiders sold 43,283 shares of company stock valued at $3,196,371. Corporate insiders own 0.05% of the company’s stock.

Baxter International Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: What is Considered a Good Return on Equity (ROE)?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply